Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

Summary: Background: The administration of broadly neutralising anti-HIV-1 antibodies before latency reversal could facilitate elimination of HIV-1-infected CD4 T cells. We tested this concept by combining the broadly neutralising antibody 3BNC117 in combination with the latency-reversing agent rom...

Full description

Bibliographic Details
Main Authors: Henning Gruell, MD, Jesper D Gunst, MD, Yehuda Z Cohen, MD, Marie H Pahus, Jakob J Malin, MD, Martin Platten, MD, Katrina G Millard, RN, Martin Tolstrup, PhD, R Brad Jones, PhD, Winnifer D Conce Alberto, Julio C C Lorenzi, PhD, Thiago Y Oliveira, PhD, Tim Kümmerle, MD, Isabelle Suárez, MD, Cecilia Unson-O'Brien, PhD, Lilian Nogueira, PhD, Rikke Olesen, PhD, Lars Østergaard, ProfMD, Henrik Nielsen, ProfMD, Clara Lehmann, MD, Michel C Nussenzweig, ProfMD, Gerd Fätkenheuer, ProfMD, Florian Klein, ProfMD, Marina Caskey, ProfMD, Ole S Søgaard, ProfMD
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:The Lancet Microbe
Online Access:http://www.sciencedirect.com/science/article/pii/S2666524721002391

Internet

http://www.sciencedirect.com/science/article/pii/S2666524721002391

Similar Items